Chiauranib, a new molecular entity exclusively discovered by the company with global patent protection, is a three-pathway tumor-targeting inhibitor with a novel mechanism. Chiauranib selectively inhibits the protein kinase targets related to tumor occurrence and development including Aurora B, CSF1R, VEGFR/PDGFR/c-Kit, exerts a multi-directional and broad-spectrum anti-tumor effect in inhibiting tumor cell proliferation, anti-tumor neovascularization, and regulating tumor immune microenvironment, and has shown good efficacy and safety in clinical trials of last-line tumor monotherapy.
Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance.Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.
Figure. Triple-pathway anti-tumor mechanisms of Chiauranib
Indications under development worldwide
- A phase 2 clinical trial of Chiauranib combined with albumin-bound paclitaxel and gemcitabine as a first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma is ongoing.
- A randomized, double-blind, controlled, multicenter phase 3 clinical trial of Chiauranib combined with paclitaxel in patients with platinum-refractory or platinum-resistant recurrent ovarian cancer has completed over 90% of the enrollment as of the disclosure date of the report, and the number of events is expected to reach in the first half of 2026;
- By the end of the reporting period, all 12 clinical study sites for phase 1b/2 clinical trial of Chiauranib in the United States had been put into operation, and the escalation of the third dose (65 mg) had been completed without dose-limiting toxicity (DLT) observed. The dose exploration at higher doses for this regimen was agreed upon by the FDA in Mar. 2025.